TKI-based regimens were associated with higher rates of disease control in metastatic translocation renal cell carcinoma.
|Videos|August 11, 2017
Dr. Gupta Discusses the Shifting Landscape of Kidney Cancer
Author(s)Shilpa Gupta, MD, Cleveland Clinic
Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses the shifting landscape of kidney cancer.
Advertisement
Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses the shifting landscape of kidney cancer.
Advertisement
Related to this article
David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.
Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.
Advertisement
Advertisement